Compile Data Set for Download or QSAR
Report error Found 241 Enz. Inhib. hit(s) with all data for entry = 11327
TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607670(US11691963, Example I-1)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607824(US11691963, Example I-2)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607825(US11691963, Example I-3)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607826(US11691963, Example I-4)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607827(US11691963, Example I-5)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607828(US11691963, Example I-6)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607829(US11691963, Example I-7)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607830(US11691963, Example I-8)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607831(US11691963, Example I-9)
Affinity DataKd:  3.00E+3nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607832(US11691963, Example I-10)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607833(US11691963, Example I-11)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607834(US11691963, Example I-12-a)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607835(US11691963, Example I-12-b)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607836(US11691963, Example I-13)
Affinity DataKd: >5.00E+3nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607837(US11691963, Example I-14)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607838(US11691963, Example I-15)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607839(US11691963, Example I-16)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607840(US11691963, Example I-17)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607841(US11691963, Example I-18)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607842(US11691963, Example I-19)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607843(US11691963, Example I-20)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607844(US11691963, Example I-21)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607845(US11691963, Example I-22)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607846(US11691963, Example I-23)
Affinity DataKd:  3.00E+3nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607847(US11691963, Example I-24)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607848(US11691963, Example I-25)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607849(US11691963, Example I-26)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607850(US11691963, Example I-27)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607851(US11691963, Example I-28)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607852(US11691963, Example I-29)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607853(US11691963, Example I-30)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607854(US11691963, Example I-31)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607855(US11691963, Example I-32)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607856(US11691963, Example I-33)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607857(US11691963, Example I-34)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607858(US11691963, Example I-35)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607859(US11691963, Example I-36-a)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607860(US11691963, Example I-36-b)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607861(US11691963, Example I-37)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607862(US11691963, Example I-38)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607863(US11691963, Example I-39)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607864(US11691963, Example I-40)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607865(US11691963, Example I-41)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607866(US11691963, Example I-42)
Affinity DataKd: <10nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607867(US11691963, Example I-43)
Affinity DataKd:  3.00E+3nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607868(US11691963, Example I-44)
Affinity DataKd:  525nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607869(US11691963, Example I-45-a)
Affinity DataKd: >5.00E+3nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607870(US11691963, Example I-45-b)
Affinity DataKd: >5.00E+3nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607871(US11691963, Example I-46)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [Y1007F,Y1008F](Human)
Ajax Therapeutics

US Patent
LigandPNGBDBM607872(US11691963, Example I-47)
Affinity DataKd:  30nMAssay Description:JAK2 (JH1domain-catalytic, Y1007F,Y1008F) kinase was expressed as N-terminal fusion to the DNA binding domain of NFkB in transiently transfected HEK2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 241 total ) | Next | Last >>
Jump to: